American Society of Hirudotherapy

Hirudin or hirudin-like factor - that is the question: insights from the analyses of natural and synthetic HLF variants

Research article published in FEBS letters (2020)

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Drug DevelopmentClinical TrialsGenomics & ProteomicsMüller C et al. · FEBS letters, 2020

Summary

The hirudin-like factor 1 (HLF1) of Hirudo medicinalis belongs to a new class of leech-derived factors. In previous investigations, HLF1 did not exhibit anticoagulatory activities.

Why This Matters for Hirudotherapy

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Citation

Hirudin or hirudin-like factor - that is the question: insights from the analyses of natural and synthetic HLF variants.

Müller C et al. · FEBS letters, 2020

DOI

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.